Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 3831 versus olanzapine for weight effects in young adults early in schizophrenia-spectrum or bipolar I illness
2017-000497-11Phase 3Completed
- Sponsor
- Alkermes
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of olanzapine + samidorphan and olanzapine in schizophrenia, schizophreniform disorder and bipolar I disorder (2 arms), sponsored by Alkermes. Primary endpoint: Percent change from baseline in body weight at week 12. Started Jun 2017; status: completed.
02
Drugs
olanzapine + samidorphanolanzapine
03
Conditions
schizophreniaschizophreniform disorderbipolar I disorder
Beyond the preview
Go deeper on 2017-000497-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000497-11.